This analysis reviews data from a Phase III randomized controlled trial involving patients with early-stage breast cancer, specifically those with clinical staging cT1-T2N0M0. The study was conducted across 34 European sites and included a total of 4,806 patients. Of these, 1,425 patients who underwent sentinel lymph node biopsy (SLNB) were randomized into two distinct groups. One group received pre-operative staging using axillary ultrasound (AUS), while the comparator group underwent staging using clinical examination only. The primary objective was to evaluate whether the addition of AUS altered the results of the subsequent SLNB procedure.
The primary outcome measured was the rate of sentinel lymph node (SLNB) positivity between the two randomized groups. The data indicated that no differences were observed in SLNB results between the AUS group and the clinical examination-only group. Specifically, positive SLNB findings were noted in 30% of patients in the AUS group compared to 32% of patients in the clinical examination-only group. Statistical analysis yielded a p-value of 0.266, indicating that the observed difference was not statistically significant. Consequently, the addition of AUS did not result in a higher detection rate of axillary metastases prior to surgery.
Secondary analyses examined baseline characteristics of the patients who tested positive for SLNB involvement. The distribution of enrollment years differed significantly between the groups, with 63% of AUS patients enrolled between 2006 and 2010, compared to 38% of AUS patients enrolled between 2001 and 2005. This difference was statistically significant with a p-value less than 0.001. Despite this temporal difference, the baseline characteristics of the SLNB-positive patients were otherwise comparable between the two groups. Additionally, the axillary tumor load was assessed and found to not differ between the groups, with a p-value of 0.156.
Regarding safety and tolerability, the input data did not report specific adverse event rates, serious adverse events, discontinuations, or general tolerability findings. Therefore, no specific safety profile for the AUS intervention could be derived from the provided dataset. The study design and population details remain consistent with the broader EORTC 10981-22023 AMAROS trial framework, though specific safety metrics were not detailed in this summary.
The results of this trial contribute to the ongoing debate regarding the utility of pre-operative imaging in axillary staging for early-stage breast cancer. Prior landmark studies have explored various methods to reduce the number of unnecessary axillary dissections. This specific analysis suggests that for patients with cT1-T2N0M0 disease, the addition of AUS does not improve the predictive value of the SLNB over clinical examination alone. The lack of difference in SLNB positivity rates implies that AUS may not add significant staging information in this cohort.
Methodological limitations inherent to the provided data include the lack of reported adverse events and the specific note regarding enrollment year distribution differences. The study relied on data from a large cohort, but the absence of detailed safety reporting limits the ability to assess the risk-benefit profile of AUS in this context. Furthermore, the follow-up duration was not reported, which restricts the ability to assess long-term outcomes or late adverse events associated with the imaging strategy.
Clinical implications of these findings suggest that clinicians should consider the cost and resource implications of performing AUS in patients with early-stage breast cancer who are candidates for SLNB. If AUS does not alter the SLNB positivity rate, its routine use may not be justified solely for staging purposes in this population. However, the decision to utilize AUS may still depend on institutional protocols and the specific clinical context of individual patients.
Several questions remain unanswered based on this dataset. The lack of reported safety data prevents a comprehensive assessment of the harms associated with AUS. Additionally, the study did not report on whether AUS influenced surgical management beyond the SLNB results, such as the rate of completion axillary dissections or overall survival. Further research is needed to clarify the role of AUS in specific subgroups or when combined with other imaging modalities.
In conclusion, this review of data from a Phase III randomized controlled trial indicates that pre-operative axillary ultrasound does not significantly change sentinel lymph node positivity rates compared to clinical examination alone in patients with early-stage breast cancer. The absolute numbers showed 30% positivity in the AUS group versus 32% in the clinical examination group, with a p-value of 0.266. While the study provides valuable insight into staging utility, the absence of detailed safety and long-term outcome data limits the ability to make definitive recommendations regarding the routine use of AUS in this setting.
